⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OCUL News
Ocular Therapeutix, Inc.
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
globenewswire.com
OCUL
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
globenewswire.com
OCUL
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
globenewswire.com
OCUL
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
globenewswire.com
OCUL
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
OCUL
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
globenewswire.com
OCUL
ZEISS advances connected cataract and refractive workflows with new digital, AI and surgical innovations at ASCRS USA - English India - English
prnewswire.com
OCUL
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
globenewswire.com
OCUL
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
OCUL
Form 8-K
sec.gov
OCUL